Patient satisfaction with primary care office-based buprenorphine/naloxone treatment

J Gen Intern Med. 2007 Feb;22(2):242-5. doi: 10.1007/s11606-006-0050-y.

Abstract

Background: Factors associated with satisfaction among patients receiving primary care-based buprenorphine/naloxone are unknown.

Objective: To identify factors related to patient satisfaction in patients receiving primary care-based buprenorphine/naloxone that varied in counseling intensity (20 vs 45 minutes) and office visit frequency (weekly vs thrice weekly).

Design and participants: One hundred and forty-two opioid-dependent subjects.

Measurements: Demographics, drug treatment history, and substance use status at baseline and during treatment were collected. The primary outcome was patient satisfaction at 12 weeks.

Results: Patients' mean overall satisfaction score was 4.4 (out of 5). Patients were most satisfied with the medication and ancillary services and indicated strong willingness to refer a substance-abusing friend for the same treatment. Patients were least satisfied with their interactions with other opioid-dependent patients, referrals to Narcotics Anonymous, and the inconvenience of the treatment location. Female gender (beta = .17, P = .04) and non-White ethnicity/race (beta = .17, P = .04) independently predicted patient satisfaction. Patients who received briefer counseling and buprenorphine/naloxone dispensed weekly had greater satisfaction than those whose medication was dispensed thrice weekly (mean difference 4.9, 95% confidence interval 0.08 to 9.80, P = .03).

Conclusions: Patients are satisfied with primary care office-based buprenorphine/naloxone. Providers should consider the identified barriers to patient satisfaction.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Buprenorphine / administration & dosage*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Naloxone / administration & dosage*
  • Office Visits*
  • Opioid-Related Disorders / drug therapy
  • Opioid-Related Disorders / epidemiology
  • Patient Satisfaction*
  • Primary Health Care* / methods
  • Treatment Outcome

Substances

  • Naloxone
  • Buprenorphine